Turci Marco, Pilotti Elisabetta, Ronzi Paola, Magnani Giacomo, Boschini Antonio, Parisi Saverio G, Zipeto Donato, Lisa Antonella, Casoli Claudio, Bertazzoni Umberto
Section of Biology and Genetics, Department of Mother and Child, University of Verona, Verona, Italy.
J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):100-6. doi: 10.1097/01.qai.0000179426.04166.12.
Human T-cell lymphotropic virus (HTLV) type II has spread among intravenous drug users (IDUs), many of whom are coinfected with HIV-1. We have investigated the rate of HTLV-II infection in 3574 Italian IDUs screened for HIV-1, HTLV-I, and HTLV-II from 1986 to the present. HTLV-II proviral load was determined by a real-time polymerase chain reaction specifically designed for tax amplification. The frequency of HTLV-II infection was 6.7% among HIV-1-positive subjects and 1.1% among HIV-1-negative subjects (P < 0.0001). For examination of AIDS progression, a group of 437 HIV-1-monoinfected subjects and another group of 96 HIV-1/HTLV-II-coinfected subjects were monitored. Enrollees were matched at entry by CD4 cell counts and followed for an average of 13 years. HIV-1/HTLV-II coinfection was associated with older age (P < 0.0001) and higher CD4 (P < 0.0001) and CD8 (P < 0.001) cell counts compared with monoinfected IDUs. The number of long-term nonprogressors for AIDS was significantly higher (P < 0.0001) among coinfected patients (13 [13.5%] of 96 patients) than HIV monoinfected patients (5 [1.1%] of 437 patients), showing that HTLV-II exerts a protective role. An increased incidence of liver disease and hepatitis C virus positivity among coinfected IDUs was observed. Five coinfected subjects undergoing antiretroviral therapy showed a significant (P < 0.05) increase in HTLV-II proviral load concomitant to a decrease in HIV-1 viremia, suggesting that the treatment is ineffective against HTLV-II infection.
人类嗜T淋巴细胞病毒II型（HTLV-II）在静脉注射吸毒者（IDU）中传播，其中许多人同时感染了HIV-1。我们调查了1986年至今对3574名接受HIV-1、HTLV-I和HTLV-II筛查的意大利IDU的HTLV-II感染率。通过专门设计用于tax扩增的实时聚合酶链反应测定HTLV-II前病毒载量。HTLV-II感染频率在HIV-1阳性受试者中为6.7%，在HIV-1阴性受试者中为1.1%（P<0.0001）。为了检查艾滋病进展情况，对一组437名HIV-1单感染受试者和另一组96名HIV-1/HTLV-II合并感染受试者进行了监测。入组者在入组时按CD4细胞计数进行匹配，平均随访13年。与单感染IDU相比，HIV-1/HTLV-II合并感染与年龄较大（P<0.0001）、CD4（P<0.0001）和CD8（P<0.001）细胞计数较高有关。合并感染患者中艾滋病长期不进展者的数量（96例患者中有13例[13.5%]）显著高于HIV单感染患者（437例患者中有5例[1.1%]）（P<0.0001），表明HTLV-II发挥了保护作用。观察到合并感染的IDU中肝病和丙型肝炎病毒阳性的发生率增加。5名接受抗逆转录病毒治疗的合并感染受试者的HTLV-II前病毒载量显著增加（P<0.05），同时HIV-1病毒血症减少，这表明该治疗对HTLV-II感染无效。
